Clinicians Still Have Concerns Regarding Melanoma Treatment Options
the Cancer Therapy Advisor take:
Two new targeted systemic therapies have been recently introduced as possible treatment options for advanced melanoma, according to an article published online in the European Journal of Cancer Care.
Participants in this study included 343 oncologists who completed online surveys between August and November 2012 (in 11 countries) and March and April 2013 (in another country), following the introduction of the two new treatment agents.
The authors analyzed the results of the surveys and found 23 clinical issues of concern across all countries. Of these 23 issues, the most common were identified as being drug toxicity and tolerability. The second most common was limited treatment effectiveness, followed by limited treatment options.
The findings of the study state that clinical professionals still have concern regarding the limitations of treatment options available to patients despite the promise of two new agents for treating advanced melanoma.
Two new targeted systemic therapies have been recently introduced as possible treatment options for advanced melanoma.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- High Red Meat Intake and Cancer
- Complete Resection of Metastatic Soft Tissue Sarcoma Associated With Improved Disease-specific Survival
- The Role of Anti-PD-1 Immunotherapy in Advanced Triple-negative Breast Cancer
- The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma
- FDA Approves Fulvestrant/Abemaciclib Combination for Breast Cancer
- FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma
- Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment
- Does Education Level Predict PSA Screening and Prostate Cancer Survival?
- Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia
- Minimal Residual Disease and Patient Genotype May Inform Relapse Risk Algorithms in ALL